Aura Biosciences, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Aura Biosciences, Inc. (AURA) had Deferred Tax Assets, Operating Loss Carryforwards of $84.24 million as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-30
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $84.24M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $55.83M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $46.00M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $40.62M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $84.24M 10-K · filed 2026-03-30 |
| 2024-12-31 | $55.83M 10-K · filed 2026-03-30 |
| 2023-12-31 | $46.00M 10-K · filed 2025-03-24 |
| 2022-12-31 | $40.62M 10-K · filed 2024-03-27 |
| 2021-12-31 | $36.29M 10-K · filed 2023-03-15 |
| 2020-12-31 | $27.92M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |